The Role of Bleeding at Implant Placement
The Role of Bleeding at Implant Placement: a Prospective Observational Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ana Castro
- Phone Number: +32 16 37 37 48
- Email: anabelen.castrosarda@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males or females American Society of Anesthesiologists classification (ASA) I or II, between 18 to 80 years of age
- Patient in good general health as documented by self-assessment.
- Patients needing implant rehabilitation in the upper or lower jaw.
- Patients must be committed to the study and must be willing to sign the informed consent.
Exclusion Criteria:
- Any systemic medical condition that could interfere with the surgical procedure or planned treatment.
- Immunosuppression, Diabetes, Anticoagulation or Antiaggregatory medication.
- Current pregnancy or breast feeding/ lactating at the time of recruitment.
- Radiotherapy or Chemotherapy in head and neck area.
- Intravenous and oral bisphosphonate therapy.
- Patients smoking >20 cigarettes a day.
- Unwillingness to return for the follow-up examination.
- Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unrealistic expectations.
Local exclusion criteria:
- Immediate implant placement after tooth extraction.
- Risk of extra bleeding due to inflammatory or infectious processes near the zone of implantation.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between bleeding during implant placement and marginal bone loss
Time Frame: 1 year
|
Peri-implant bone loss after 1 year from the implant placement
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between bleeding during implant placement and implant stability quotient (ISQ) values
Time Frame: 3 months
|
Correlation between bleeding during implant placement and implant stability quotient (ISQ) values
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S58575
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
NCT02094885CompletedHemorrhage | Cardiovascular Bleeding | Vascular Bleeding
-
NCT05290857RecruitingGastroIntestinal Bleeding | Anticoagulant-induced Bleeding
-
NCT02227992CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma Bleeding
-
NCT03840057UnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal Bleeding
-
NCT06143787RecruitingBleeding From Teeth | Bleeding Prophylaxis
-
NCT06939907Not yet recruitingLower Gastrointestinal Bleeding | Diverticular Bleeding
-
NCT00405613CompletedBleeding Complication
-
NCT06881628RecruitingCirrhosis | Variceal Bleeding | Upper Gastrointestinal Bleeding (UGIB)
-
NCT03090945RecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal Bleeding
-
NCT01675856CompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active Bleeding